Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
RESEARCH TOOLSreports
Holding VTGN?
Track your performance easily
Earnings Data
Report Date
Feb 18, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.51Last Year’s EPS
-0.22Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 29, 2018
|% Change Since: -6.41%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Positive
The call highlighted significant progress in Vistagen's novel neuroscience pipeline, with multiple successful trials and ongoing developments. Despite increased expenses and potential delays in protocol submissions, the company's strong financial position and strategic advancements indicate positive momentum.Company Guidance
During Vistagen's Q2 2025 earnings call, the company provided guidance on several key metrics and upcoming milestones. Research and development expenses increased to $10.2 million for the quarter ended September 30, 2024, compared to $3.9 million in the prior year, driven by their ongoing PALISADE Phase III program for fasedienol in social anxiety disorder (SAD). General and administrative expenses also rose to $4.2 million from the previous year's $3.2 million due to increased headcount and professional fees. The net loss attributable to common stockholders was $13 million, up from $6.6 million. As of September 30, 2024, the company reported $97.6 million in cash and marketable securities. Vistagen remains focused on executing its Phase III trials for fasedienol, with results expected in 2025, while advancing its itruvone program in major depressive disorder towards Phase IIb development in the U.S. and preparing PH80 for a U.S. IND submission targeting menopausal hot flashes.Advancement of Neuroscience Pipeline
Vistagen is progressing with its unique neuroscience pipeline featuring intranasal pherine therapies, with differentiated mechanisms and safety profiles. Notable candidates include fasedienol for social anxiety disorder, itruvone for major depressive disorder, and PH80 for menopausal hot flashes.
Successful Phase III and Phase II Trials
Statistically significant efficacy and favorable safety data observed in Phase III trial for fasedienol (social anxiety disorder), Phase IIa trial for itruvone (major depressive disorder), and Phase IIa trial for PH80 (menopausal hot flashes).
Strong Financial Position
As of September 30, 2024, Vistagen reported $97.6 million in cash, cash equivalents, and marketable securities.
Initiation of New Trials
Initiated PALISADE-3 and PALISADE-4 Phase III trials for fasedienol on time, with 16 sites activated for PALISADE-3 and 12 for PALISADE-4.
---
VTGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VTGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $3.12 | $3.14 | +0.64% |
| Aug 13, 2024 | $3.39 | $3.28 | -3.24% |
| Jun 11, 2024 | $3.77 | $3.69 | -2.12% |
| Feb 13, 2024 | $4.90 | $5.39 | +10.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does VistaGen Therapeutics (VTGN) report earnings?
VistaGen Therapeutics (VTGN) is schdueled to report earning on Feb 18, 2025, TBA Not Confirmed.
What is VistaGen Therapeutics (VTGN) earnings time?
VistaGen Therapeutics (VTGN) earnings time is at Feb 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VTGN EPS forecast?
VTGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.51.
---